BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18028420)

  • 21. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
    Buitenhuis M; Verhagen LP; Cools J; Coffer PJ
    Cancer Res; 2007 Apr; 67(8):3759-66. PubMed ID: 17440089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia.
    Ziegler B; Peitsch WK; Reiter A; Marx A; Goerdt S; Géraud C
    JAMA Dermatol; 2015 Jul; 151(7):766-9. PubMed ID: 25923837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
    Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
    J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12.
    Sada A; Katayama Y; Yamamoto K; Okuyama S; Nakata H; Shimada H; Oshimi K; Mori M; Matsui T;
    Ann Hematol; 2007 Dec; 86(12):855-63. PubMed ID: 17701174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
    Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
    Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2010; 72(1-2):55-70. PubMed ID: 20726440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
    Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
    Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint.
    Lambert F; Heimann P; Herens C; Chariot A; Bours V
    J Mol Diagn; 2007 Jul; 9(3):414-9. PubMed ID: 17591942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Ng HJ; Tan DC; Yiu RC; How GF
    Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
    Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
    Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity.
    Chung KF; Hew M; Score J; Jones AV; Reiter A; Cross NC; Bain BJ
    Eur Respir J; 2006 Jan; 27(1):230-2. PubMed ID: 16387954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
    Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA
    Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.
    Rives S; Alcorta I; Toll T; Tuset E; Estella J; Cross NC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):663-5. PubMed ID: 16344672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
    Kim DS; Lee S; Choi CW
    Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427
    [No Abstract]   [Full Text] [Related]  

  • 37. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
    Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
    Miyazawa K; Kakazu N; Ohyashiki K
    Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.